CBG-MEB Netherlands Drug Registration: Indian Generic Medicine Supplier Guide

The Dutch Generic Medicines Market at a Glance

The Netherlands is one of Europe's most competitive generic markets. Hospital pharmacies, community pharmacy chains, wholesalers and parallel distributors all buy on price, but they also expect flawless documentation and dependable supply. For buyers looking to import medicines from India to the Netherlands, the opportunity is real, but only for products that sit inside the European Union's marketing authorisation and manufacturing framework.

This guide explains how the system works, which documents Dutch partners typically ask for, and how a merchant exporter such as Tuli Enterprise supports the process. It is general guidance only. Always confirm current requirements with the relevant authority before committing to an order.

Who Regulates Medicines in the Netherlands

Two bodies matter most to importers:

• CBG-MEB (Medicines Evaluation Board): assesses and grants national marketing authorisations and takes part in European procedures.
• IGJ (Health and Youth Care Inspectorate): issues and supervises manufacturing and import authorisations and wholesale distribution authorisations, and carries out inspections.

At European level, the European Medicines Agency coordinates the centralised procedure. Dutch rules follow EU pharmaceutical legislation, so much of what applies in the Netherlands applies across the EU and EEA.

Marketing Authorisation: Three Routes

No medicine can be placed on the Dutch market without a marketing authorisation. For generics, the usual routes are:

1. National procedure: submitted directly to CBG-MEB for the Dutch market only.
2. Mutual recognition or decentralised procedure: used when the product is intended for several EU member states, with the Netherlands acting as a concerned or reference state.
3. Centralised procedure: applicable to certain product categories and handled at EU level.

Generic applications are normally built on a CTD-format dossier (Modules 1 to 5) with bioequivalence evidence against the reference product, quality data and stability data suited to the EU climatic zone. The authorisation is held by a legal entity established in the EU or EEA, not by an Indian exporter. In practice, that holder is your company or a Dutch or European partner who files the dossier and carries the pharmacovigilance responsibilities.

Import Authorisation and Batch Release

Medicines manufactured outside the EU must be imported by a holder of a manufacturing and import authorisation issued by the IGJ. Key points for buyers:

• A Qualified Person (QP) at the importing site certifies each batch for release in the EU, which includes confirming that the manufacturing site follows GMP standards equivalent to EU requirements.
• The Indian manufacturing site generally needs to be inspected or otherwise accepted by an EU authority, and the QP will want evidence of current GMP compliance.
• Import testing in the EU/EEA is typically required unless specific arrangements apply.

Distribution of the released product to pharmacies or hospitals then requires a wholesale distribution authorisation under Good Distribution Practice. If you are a trader without these licences, you will need to work through a licensed importer or wholesaler.

Documents Dutch Buyers Usually Request

Request lists vary by buyer, but a well-prepared supplier should be ready to provide:

• CTD dossier or access to the relevant modules, subject to the agreed commercial structure
• Certificate of Pharmaceutical Product (COPP) and Free Sale Certificate
• Certificate of Analysis (CoA) for each batch
• Stability data, including long-term and accelerated studies
• Evidence of GMP status of the manufacturing site, from our GMP-certified manufacturing partners
• Product specifications, method summaries and, where relevant, API source information
• Artwork and pack specifications for review

Tuli Enterprise supplies COPP, CoA, CTD dossiers, Free Sale Certificate and stability data through our manufacturing partners. Our insights library includes further explainers on documentation.

Labelling, Language and Packaging

Dutch labelling is a frequent cause of delays. Plan for the following:

• Package leaflet and outer carton text in Dutch, in line with the approved product information
• Braille on the outer packaging name where required by EU rules
• Batch number and expiry date in the agreed format
• Safety features and unique identifier requirements for applicable prescription products under the EU Falsified Medicines framework

Many importers choose to have final packaging or relabelling done in the EU under their own licence. Others ask the manufacturer to ship fully finished Dutch-language packs. Decide this early because it affects artwork approval, MOQ and lead time.

Pricing, Reimbursement and Tendering

Price pressure is intense. Dutch health insurers operate preferential policies for many generics, and hospitals run competitive tenders. National bodies manage reimbursement listings, so a product's commercial success depends on being priced and supplied reliably, not only on holding an authorisation. Buyers should therefore ask suppliers about capacity, safety stock and the ability to react to short-notice volume changes, since shortages can be costly in this market.

Practical Steps for a New Importer or Distributor

1. Define your product list: start with molecules where an EU-compliant dossier and a suitable manufacturing site already exist. Browse our product catalogue or filter by therapeutic area.
2. Confirm your licence position: check whether you hold, or will partner with a holder of, the IGJ import and wholesale authorisations.
3. Clarify the authorisation route: national, decentralised or an existing authorisation you can supply under.
4. Request samples and documents: evaluate CoA, stability data and GMP evidence before placing a trial order.
5. Agree artwork and packaging: confirm Dutch text, pack sizes and serialisation arrangements.
6. Place a first order: agree MOQ, lead time, Incoterms and quality agreements in writing.

MOQ and Lead Time Expectations

MOQ depends on the product, pack format and whether custom Dutch-language packaging is needed. Standard export packs usually allow smaller trial orders, while customised packs generally need a full batch or an agreed minimum. Lead times are shaped by batch scheduling, artwork approval and quality release steps, so we provide a product-specific estimate with each quotation rather than a generic figure.

Private Label and Contract Manufacturing

If you hold, or plan to apply for, your own marketing authorisation, a dedicated manufacturing arrangement may suit you better than buying finished stock. Through our contract manufacturing service, we connect buyers with GMP-certified manufacturing partners for third-party and private-label production, with specifications, packaging and documentation aligned to your requirements. You can also see how we work in other regions on our countries page.

Why Work with a Merchant Exporter

A merchant exporter consolidates several manufacturers into one commercial relationship, helping you compare options, coordinate documents and manage shipments. Tuli Enterprise, based in New Delhi, exports to more than 95 countries and is a member of PHARMEXCIL and FPME. We do not hold manufacturing certifications ourselves; quality certifications belong to our manufacturing partners, and we help you verify the documents you need for your own compliance file.

Request a Quote

If you are evaluating Indian generics for the Netherlands, send us your product list, target strengths, pack preferences and licence position through our contact page. You can also message us on WhatsApp at wa.me/919654308142 or email [email protected], and our team will respond with documentation availability, indicative MOQ and lead time.